Concise overview articles of key topics in neurodegeneration, which can be read wherever you are, whenever suits you.
Find out more here.
Announcing the launch of Mini Reviews
New Thematic Series - AI in Dementia
Alzheimer's Research & Therapy presents a thematic series focusing on the use of artificial intelligence, machine learning and related techniques in dementia research.
Find out more about the series here.
Articles
-
-
Effect of the ABCA1 agonist CS-6253 on amyloid-β and lipoprotein metabolism in cynomolgus monkeys
-
Fully automated and highly specific plasma β-amyloid immunoassays predict β-amyloid status defined by amyloid positron emission tomography with high accuracy
-
Anticipated reactions to learning Alzheimer’s disease biomarker results
-
Near-infrared light reduces β-amyloid-stimulated microglial toxicity and enhances survival of neurons: mechanisms of light therapy for Alzheimer’s disease
-
Stem cell factor and granulocyte colony-stimulating factor reduce β-amyloid deposits in the brains of APP/PS1 transgenic mice
-
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
-
Cerebral microbleeds: overview and implications in cognitive impairment
-
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
-
Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice?
Early Career Researcher Reviewer Panel
Interested in an introduction to peer reviewing articles for Alzheimer's Research & Therapy?
Find out more about our ECR Peer Reviewer Panel!
Aims and scope
Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports.
Although the primary focus is Alzheimer's disease, the scope encompasses translational research into other neurodegenerative diseases.
Published Thematic Series
Latest Tweets
View Twitter timeline
Your browser needs to have JavaScript enabled to view this timeline
Alzheimer's blogs from BMC
Failed to load RSS feed.
Affiliated with
Annual Journal Metrics
-
Speed
26 days to first decision for all manuscripts
58 days to first decision for reviewed manuscripts only
130 days from submission to acceptance
18 days from acceptance to publication
Citation Impact
6.982 - 2-year Impact Factor
8.076 - 5-year Impact Factor
1.657 - Source Normalized Impact per Paper (SNIP)
2.802 - SCImago Journal Rank (SJR)
Usage
1,249,151 downloads (2021)
1,767 Altmetric mentions